These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia. Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725 [TBL] [Abstract][Full Text] [Related]
24. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Chan G; Kalaitzidis D; Usenko T; Kutok JL; Yang W; Mohi MG; Neel BG Blood; 2009 Apr; 113(18):4414-24. PubMed ID: 19179468 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia. Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592 [TBL] [Abstract][Full Text] [Related]
26. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease. An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297 [TBL] [Abstract][Full Text] [Related]
27. Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia. Louka E; Povinelli B; Rodriguez-Meira A; Buck G; Wen WX; Wang G; Sousos N; Ashley N; Hamblin A; Booth CAG; Roy A; Elliott N; Iskander D; de la Fuente J; Fordham N; O'Byrne S; Inglott S; Norfo R; Salio M; Thongjuea S; Rao A; Roberts I; Mead AJ J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33416891 [TBL] [Abstract][Full Text] [Related]
28. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice. Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680 [TBL] [Abstract][Full Text] [Related]
29. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells. Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766 [TBL] [Abstract][Full Text] [Related]
30. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders. Miles DK; Freedman MH; Stephens K; Pallavicini M; Sievers EL; Weaver M; Grunberger T; Thompson P; Shannon KM Blood; 1996 Dec; 88(11):4314-20. PubMed ID: 8943868 [TBL] [Abstract][Full Text] [Related]
32. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Chang TY; Dvorak CC; Loh ML Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700 [TBL] [Abstract][Full Text] [Related]
33. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals. Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296 [TBL] [Abstract][Full Text] [Related]
34. Interleukin (IL)-10, but not IL-4 or IL-13, inhibits cytokine production and growth in juvenile myelomonocytic leukemia cells. Iversen PO; Hart PH; Bonder CS; Lopez AF Cancer Res; 1997 Feb; 57(3):476-80. PubMed ID: 9012477 [TBL] [Abstract][Full Text] [Related]
36. Lineage-dependent skewing of loss of heterozygosity (LOH) of KRAS gene in a case of juvenile myelomonocytic leukemia. Tokuda K; Eguchi-Ishimae M; Iwabuki H; Kawakami S; Tauchi H; Ishii E; Eguchi M Eur J Haematol; 2015 Feb; 94(2):177-81. PubMed ID: 24766281 [TBL] [Abstract][Full Text] [Related]